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Summary
The striatum is widely viewed as the fulcrum of pathophysiology in Parkinson's disease (PD) and 
L-DOPA-induced dyskinesia (LID). In these disease states, the balance in activity of striatal direct 
pathway spiny projection neurons (dSPNs) and indirect pathway spiny projection neurons (iSPNs) 
is disrupted, leading to aberrant action selection. However, it is unclear whether countervailing 
mechanisms are engaged in these states. Here we report that iSPN intrinsic excitability and 
excitatory corticostriatal synaptic connectivity were lower in PD models than normal; L-DOPA 
treatment restored these properties. Conversely, dSPN intrinsic excitability was elevated in tissue 
from PD models and suppressed in LID models. Although the synaptic connectivity of dSPNs did 
not change in PD models, it fell with L-DOPA treatment. In neither case, however, was the 
strength of corticostriatal connections globally scaled. Thus, SPNs manifested homeostatic 
adaptations in intrinsic excitability and in the number but not strength of excitatory corticostriatal 
synapses.
The striatum is a major component of the basal ganglia circuitry controlling goal-directed 
action selection and habits1. Spiny projection neurons (SPNs) constitute the vast majority of 
striatal neurons and are organized into two distinct GABAergic projection systems: dSPNs 
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that directly project to the interface of the basal ganglia with the rest of the brain, promoting 
action selection and iSPNs that indirectly project to the interface through the globus pallidus 
externa, suppressing actions2. These two types of SPNs are differentially modulated by 
dopamine released by substantia nigra pars compacta (SNc) neurons. Dopamine decreases 
the excitability of iSPNs through D2 dopamine receptor (D2R) signaling and increases the 
excitability of dSPNs through D1 dopamine receptor (D1R) signaling. This is accomplished 
through modulation of both intrinsic conductances and synaptic plasticity. Thus, event-
driven changes in the spiking of SNc dopaminergic neurons bidirectionally modulate 
intrinsic excitability and on-going spiking in these two SPN populations, as well as the 
induction of plasticity at corticostriatal synapses, shaping future SPN activity and goal 
directed behavior3, 4.
In PD, SNc dopaminergic neurons are progressively lost, disrupting this bidirectional 
modulation5, 6. The slowness of movement and rigidity that characterize PD are attributable 
to hyperactivity in iSPNs and concomitant hypoactivity in dSPNs. This imbalance has long 
been thought to underlie the persistent action suppression characteristic of PD7. The 
administration of L-DOPA – a dopamine precursor – boosts the production and release of 
dopamine in the striatum, restoring basal striatal tone, the balance between direct and 
indirect pathways and movement control. However, as the disease progresses and more SNc 
dopaminergic neurons are lost, the dose of L-DOPA needed to restore movement rises and 
the mechanisms for controlling extracellular dopamine are lost8, 9, 10, 11. This combination 
leads to slow, poorly regulated fluctuations in extracellular dopamine concentrations. These 
fluctuations result in abnormally prolonged periods of D1R stimulation and the emergence 
of abnormal movements called dyskinesia8, 12, 13.
Although there are a variety of striatal biochemical changes that accompany PD and L-
DOPA-induced dyskinesia (LID), the synaptic and intrinsic adaptations in SPNs driven by 
aberrant network activity in these states are not well understood. In particular, it is not 
known whether homeostatic plasticity ameliorates the perturbations in spiking expected to 
accompany the loss and restoration of dopamine signaling. In other neurons, two types of 
homeostatic plasticity have been described: intrinsic and synaptic14. Intrinsic homeostatic 
plasticity refers to alterations in the postsynaptic transformation of synaptic currents into 
spiking; increasing or decreasing the gain of this relationship can be used to keep average 
spike rate within a desired range. Synaptic homeostatic plasticity refers to global alterations 
in the strength of synaptic connections to achieve the same endpoint. To preserve the 
relative importance of synaptic inputs in driving activity, synaptic strength is typically 
scaled; that is, all inputs are increased or decreased in strength by the same factor15. If 
cellular learning is encoded in relative synaptic weight, then scaling will preserve it.
By virtue of their complementary modulation by dopamine, dSPNs and iSPNs would be 
expected to undergo opposite homeostatic adaptations in PD. This inference is consistent 
with the demonstration that following dopamine depleting lesions, iSPNs undergo a 
pronounced pruning of excitatory axospinous synapses, but dSPN synaptic density remains 
unchanged16. However, the changes associated with LID are more difficult to predict 
because of inferred alterations in dopamine receptor signaling17, 18. For example, 
biochemical studies show that the induction of LID is accompanied by up-regulation in 
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ERK/AP-1 dependent signaling specifically in dSPNs8, 12, 13, 19. Recent anatomical studies 
suggest that the lost iSPN synaptic connections are at least partially restored following high-
dose L-DOPA treatment20, 21, 22. However, it is not clear from these studies whether there 
are intrinsic changes that accompany the alterations in synaptic connectivity or whether 
synaptic strength is scaled in a way that will preserve learned associations presumably stored 
in the strength of corticostriatal synapses.
The studies reported here were designed to answer some of these questions. They show that 
iSPNs and dSPNs undergo largely complementary forms of intrinsic and synaptic plasticity 
following lesioning of SNc dopaminergic neurons and L-DOPA treatment. Many of these 
homeostatic changes were cell-specific (i.e. iSPNs decreased excitability, compensating for 
a loss of inhibitory D2R stimulation, whereas dSPNs increased excitability to compensate 
for a loss of excitatory D1R stimulation); thus, these adaptations would serve to normalize 
the average spiking rate of SPNs in the face of changing dopamine concentrations. However, 
the strength of SPN corticostriatal synapses was not globally scaled in parallel, potentially 
leading to alterations in the temporal pattern of activity in vivo.
Results
SPN intrinsic excitability was altered in PD and LID models
One of the most prominent differences between iSPNs and dSPNs in healthy mice is their 
intrinsic excitability23, 24, 25. To determine if dopamine depletion or L-DOPA treatment 
altered this relationship, two sets of experiments were performed to characterize somatic and 
dendritic excitability. The excitability of the somatic membrane and axon initial segment 
(AIS) was assessed by injecting current steps of increasing amplitude through the patch 
electrode and measuring the resultant spiking. In control iSPNs, the relationship between 
injected current and spike frequency was similar to that described in previous studies26. In 
iSPNs from parkinsonian mice, intrinsic excitability was depressed, as predicted by a 
homeostatic response to the loss of inhibitory D2R signaling (Fig. 1a,b); that is, more current 
was required to achieve a similar level of spiking (for example, the number of action 
potentials generated by 0.2nA current injection dropped from a median of 8 in control mice 
to a median of 2 in parkinsonian mice (Fig. 1a,b)). High-dose L-DOPA treatment 
normalized intrinsic excitability, shifting the relationship between current and spiking back 
into the normal range (Fig. 1a,b). Other intrinsic properties of iSPNs were modestly, but 
often significantly changed (Supplementary Table 1). For example, the amplitude of spike 
after-hyperpolarization was increased in iSPNs from parkinsonian mice, likely contributing 
to the diminished somatic/AIS excitability.
Although dendritic excitability in SPNs cannot be directly assessed, dendritic Ca2+ entry 
evoked by back-propagating action potentials (bAPs) provides a surrogate measure25, 27. 
Using two-photon laser scanning microscopy (2PLSM) to measure changes in the 
fluorescence of the Ca2+ indicator Fluo-4, reliable dendritic Ca2+ signals were evoked by 
theta-burst stimulation of the somatic membrane. In iSPNs from parkinsonian mice, this 
Ca2+ signal was significantly reduced in distal dendritic shafts and spines (Fig. 1c-e). L-
DOPA treatment restored iSPN dendritic excitability (Fig. 1c-e) (low dose L-DOPA was 
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also effective; shaft median: 1.4, lower quartile: 0.9, upper quartile: 1.8 and head median: 
1.4, lower quartile: 1.0, upper quartile: 1.9; n=16).
The intrinsic excitability of dSPNs also was altered in a manner consistent with a 
homeostatic mechanism. In control dSPNs, the relationship between injected current and 
spike frequency was similar to that described in previous studies23. In dSPNs from 
parkinsonian mice, intrinsic excitability was significantly elevated, consistent with a 
homeostatic response to the loss of facilitating D1R signaling (Fig. 2a,b); that is, less current 
was required to achieve a similar level of spiking (for example, 0.2 nA current injection 
evoked a median of 0 spikes in control dSPNs, which increased to a median of 11 spikes in 
parkinsonian dSPNs; p<0.05). High-dose L-DOPA treatment partially normalized intrinsic 
excitability, shifting the relationship between current and spiking back toward the normal 
range (Fig. 2a,b). Other intrinsic properties of dSPNs were altered by lesioning and L-
DOPA treatment (Supplementary Table 2). Rheobase and action potential amplitude were 
decreased whereas input resistance was increased in parkinsonian and dyskinetic mice 
compared to control. In contrast, the after-hyperpolarization amplitude was increased in 
dyskinetic mice compared to both control and parkinsonian mice, contributing to the partial 
restoration of soma/AIS excitability.
Dendritic excitability in dSPNs – as estimated by dendritic Ca2+ signal evoked by bAPs – 
was stable after 6-OHDA lesioning (Fig. 2e). However, after L-DOPA treatment (including 
low dose L-DOPA; shaft median: 1.0, lower quartile: 0.7, upper quartile: 1.6 and head 
median: 1.0, lower quartile: 0.8, upper quartile: 1.5; n=40), the excitability of distal 
dendrites fell significantly (Fig. 2e), in parallel with somatic excitability.
Dendritic length was reduced in PD models
As the difference in intrinsic excitability of dSPNs and iSPNs is partially attributable to 
dSPNs having larger dendritic trees than iSPNs, it is possible that the excitability changes 
induced by lesioning and L-DOPA treatment were a reflection of changing anatomy23. To 
test this hypothesis, the dendritic trees of iSPNs were filled with Alexa 568 and 
reconstructed using 2PLSM. Contrary to the predictions of this hypothesis, lesioning 
dopaminergic neurons significantly reduced the complexity of the iSPN dendritic arbor (Fig. 
3). The number of branch points as a function of distance from the soma was decreased both 
proximally and distally (Fig. 3b). Total dendritic length (Fig. 3c) and number of primary 
dendrites (Fig. 3e) were significantly decreased as well. Moreover, high-dose L-DOPA 
treatment to parkinsonian mice did not reverse the reduction iSPN dendritic branching (Fig. 
3b-e).
As with iSPNs, lesioning dopaminergic neurons significantly reduced the complexity of the 
dSPN dendritic arbor (Fig. 4a). The number of branch points as a function of distance from 
the soma was decreased both proximally and distally (Fig. 4b). Total dendritic length, 
number of branch points, and number of primary dendrites were significantly decreased 
(Fig. 4c-e). Dyskinesiogneic L-DOPA treatment to parkinsonian mice did not reverse the 
reduction dSPN dendritic branching. Extending L-DOPA treatment for 28 days (injections 
every other day)did not restore dendrites either (Supplementary Fig. 2).
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These results suggest that the intrinsic homeostatic plasticity seen in response to lesioning 
and L-DOPA treatment were not attributable to changes in dendritic anatomy. Furthermore, 
because these changes were qualitatively similar in dSPNs and iSPNs and unaltered by L-
DOPA treatment, it is likely that the dendrites were responding to some factor other than 
dopamine that was lost by lesioning mesencephalic neurons.
L-DOPA treatment altered spine density
As previously described16, lesioning of the dopaminergic innervation was accompanied by a 
significant reduction in iSPN spine density (Fig. 5). The reduction was found in both 
proximal (<80μm from the soma) and distal (>80μm from the soma) dendrites. High-dose L-
DOPA treatment, but not low dose L-DOPA (proximal median: 0.7, lower quartile: 0.5, 
upper quartile: 0.9; distal median: 0.7, lower quartile: 0.6, upper quartile: 0.8; n=9), reversed 
this loss, bringing spine density in both proximal and distal dendrites to values that were not 
significantly different from controls (Fig. 5). Despite the restoration in spine density with 
high-dose L-DOPA, estimates of total spine number remained below control levels as a 
result of decreased dendritic length (Fig. 5e)
In agreement with previous work16, dSPN spine density did not change significantly 
following 6-OHDA lesioning (Fig. 6). However, because of the loss of dendritic length, the 
estimated total number of dSPN axospinous synapses fell with lesioning. In contrast, both 
proximal and distal spine density in dSPNs fell with low dose L-DOPA (proximal median: 
0.8, lower quartile: 0.7, upper quartile: 1.1 n=10; distal median: 0.8, lower quartile: 0.6, 
upper quartile: 0.8 n=13) and high-dose L-DOPA treatment (Fig. 6c,d), as did the estimate 
of total number of spines (Fig. 6e).
Adaptations in corticostriatal connectivity
To determine the functional significance of changes in spine density (Fig. 5&6), 
electrophysiological and/or optogenetic studies were conducted. As a first step, the source of 
the presynaptic element at axospinous synapses was determined. In control rodents, the vast 
majority of these axospinous synapses are corticostriatal28, 29. To interrogate corticostriatal 
axospinous circuitry, Thy1-ChR2 transgenic mice were used30. In these mice, ChR2 
expression in glutamatergic neurons appears to be limited to corticostriatal pyramidal 
neurons and not extend to thalamostriatal neurons31. To map corticostriatal synapses, the 
sCRACm approach32 was used in ex vivo brain slices from bi-transgenic mice expressing 
ChR2 in cortical neurons and a fluorescent reporter of SPN subtype31. At spines where there 
was a cortical terminal expressing ChR2, a blue laser flash induced glutamate release, which 
was detected as a postsynaptic current (Fig. 7&8).
In sham lesioned mice, approximately 75% of the iSPN spines responded to blue laser 
flashes (Fig. 7c,d), consistent with prior studies31. This was true in both proximal and distal 
dendrites. This percentage is very close to that predicted from anatomical studies29, 33. In 
collateral studies where intralaminar thalamic neurons were induced to express ChR2, about 
30% of iSPN spines were found to be responsive, suggesting that few, if any, spines had 
‘silent’ synapses31. Following 6-OHDA lesioning, the percentage of spines with a detectable 
cortical terminal fell to approximately 40% (Fig. 7c,d). Thus, lesion-induced spine pruning 
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was prominent at corticostriatal axospinous synapses. Surprisingly, following high-dose L-
DOPA treatment, the proportion of spines responsive to optogenetic activation of 
corticostriatal terminals returned to near control values (Fig. 7c,d).
In addition to the presence of functional AMPARs, the sCRACm mapping yields 
information about synaptic strength. Following 6-OHDA lesioning, the average amplitude of 
corticostriatal synaptic responses in iSPNs increased (Fig. 7e), in agreement with previous 
work using electrical stimulation of cortical axons and Ca2+ replacement with Sr2+34. High-
dose L-DOPA treatment normalized the amplitude of the corticostriatal responses (Fig. 7e). 
These changes are consistent with the known role of D2R signaling in promoting long-term 
depression of corticostriatal synapses2, 35. However, they were not consistent with 
homeostatic scaling, which would predict a downward (leftward) shift in synaptic strength in 
the PD model and an upward (rightward) shift in the LID model. Rather, excitatory synaptic 
strength increased in the PD model when iSPN intrinsic excitability was falling and then 
decreased when iSPN intrinsic excitability was rising in the LID model.
To provide an additional level of confidence that this pattern was not the product of the 
optogenetic approach, Sr2+ miniature excitatory postsynaptic currents (mEPSCs) evoked by 
cortical stimulation in parasagittal brain slices were examined. Because the parkinsonian 
condition had been examined previously34, these studies focused on the LID model. As 
predicted from the optogenetic experiments, corticostriatal Sr2+ mEPSC amplitude in the 
sham and L-DOPA-treated conditions was not significantly different (sham median: 
14.13pA, lower quartile: 12.63pA, upper quartile: 15.25pA, n=8; dyskinetic median: 
14.85pA, lower quartile: 12.85pA, upper quartile: 16.46pA, n=10; Mann Whitney p=0.49).
The data shown demonstrate that following lesioning of dopamine neurons, the number of 
corticostriatal synapses on iSPNs fell, but their average strength rose. Conversely, with high-
dose L-DOPA treatment, the number of corticostriatal synapses rose, but their average 
strength fell. The opposing alterations in number and strength of synapses might effectively 
cancel one another, leaving total synaptic currents constant. To test this prediction, iSPNs 
were loaded with Cs+ to make them as electrotonically compact as possible and to lessen the 
impact of the changes in dendritic excitability described above; then corticostriatal axons 
were optogenetically stimulated by a full-field blue light flash. In iSPNs from sham lesioned 
mice (as well as those from treated mice) the optogenetically evoked synaptic response was 
sub-linearly related to stimulus intensity (Fig. 7h); this was expected as progressively larger 
dendritic depolarization diminishes the driving force for synaptic currents. Nevertheless, at 
both low and high stimulation intensities, the evoked synaptic responses of iSPNs in slices 
from control, parkinsonian and LID mice were indistinguishable (Fig. 7i,j).
dSPN corticostriatal connectivity fell in the LID model. As with iSPNs, electrophysiological 
and optogenetic approaches were used to characterize the properties of dSPN synapses in 
each model. The origin of the presynaptic element at axospinous synapses was determined 
using sCRACm, as described above. In control and lesioned Thy1-ChR2 mice, 
approximately 75% of the dSPN spines responded to optogenetic activation (Fig. 8c,d). This 
was true in both proximal and distal dendrites. The percentage was indistinguishable from 
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that in iSPNs. Following high-dose L-DOPA treatment, this percentage fell significantly 
(Fig. 8c,d), demonstrating that corticostriatal synapses were being pruned.
The sCRACm approach also was used to determine if there were alterations in synaptic 
strength following LID induction. In dSPNs from both parkinsonian and LID mice, there 
was a significant reduction in the relative abundance of large amplitude corticostriatal 
synaptic currents(Fig. 8e). However, using electrical stimulation of sensorimotor cortex 
axons and Sr2+ replacement of extracellular Ca2+ to generate asynchronous miniature 
EPSCs, no differences were seen in the distribution of synaptic amplitudes across conditions 
(control median: 15.2pA, lower quartile: 11.5pA, upper quartile: 17.2pA, n=17; 
parkinsonian median: 14.9pA, lower quartile: 13.5pA, upper quartile: 17.0pA, n=12; 
dyskinetic median: 14.2pA, lower quartile: 12.7pA, upper quartile: 15.8pA, n=13; Kruskal-
Wallis p=0.70). Given that many regions of cortex project to SPNs36, it is possible that this 
apparent discrepancy is a consequence of preferential down-regulating synaptic connections 
arising from limbic or sensory cortical regions (which were not assayed in Sr2+experiments) 
following LID induction.
Taken together, these results suggest that in the absence of dopamine (i.e. in parkinsonian 
and LID mice during the “off-state”), there was a reduction in the total strength of 
corticostriatal synapses on dSPNs. This reduction in synaptic strength was complemented in 
the LID model by a reduction in the number of corticostriatal axospinous synapses. As a 
consequence, the aggregate cortical synaptic response in dSPNs should be smaller in tissue 
from PD and LID models. To test this prediction, the cortical inputs to dSPNs were 
optogenetically stimulated in the Thy1-ChR2 transgenic mice. As with iSPNs, the 
optogenetically evoked post-synaptic currents were sub-linearly related to stimulus intensity 
(Fig. 8h). More importantly, the evoked synaptic response of dSPNs in slices from PD and 
LID mice was smaller than that in tissue from control mice at both low and high stimulation 
intensities (Fig. 8i,j).
Extrasynaptic NMDAR currents were correlated with spine loss
Another feature of striatal glutamatergic synaptic transmission that has been reported to 
change with lesioning of the dopaminergic neurons and LID is the balance between synaptic 
and extrasynaptic NMDA receptors (NMDARs)37. However, none of the studies that have 
been conducted to date have distinguished between glutamatergic synapses on iSPNs and 
dSPNs. To fill this gap, iSPNs were patch-clamped and the ratio between NMDAR and 
AMPAR currents measured. Initially, the NMDAR/AMPAR ratio was assessed using two-
photon laser uncaging of glutamate (2PLUG) on spine heads. These studies revealed that the 
NMDAR/AMPAR at iSPN spines increased following 6-OHDA lesioning and then returned 
to normal values after high-dose L-DOPA treatment (Fig. 9c) and low dose L-DOPA 
(median: 1.1, lower quartile: 0.9, upper quartile: 1.6; n=55).
Although these studies demonstrate an important postsynaptic adaptation, they suffer from 
two limitations. First, even when the intensity of the uncaging laser is adjusted to mimic 
naturally occurring minimal synaptic events (∼5pA), there was no certainty that only 
synaptic receptors are being stimulated. Second, the type of synapse (corticostriatal or 
thalamostriatal) was unknown. Overcoming these limitations is important for a number of 
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reasons, not the least of which is that the NMDAR/AMPAR of thalamostriatal and 
corticostriatal synapses differ in control mice, making sampling bias a potential factor38. To 
address these shortcomings, corticostriatal axons were optically stimulated in slices from 
Thy1 transgenic mice described above and the NMDAR/AMPAR ratio measured. In normal 
recording conditions, this ratio did not change as a function of treatment condition (Fig. 9e). 
However, when glutamate uptake was blocked using DL-threo-β-benzyloxyaspartic acid 
(TBOA), the NMDAR/AMPAR ratio was significantly elevated following 6-OHDA 
lesioning (Fig. 9f). These data are consistent with the proposition that the abundance of 
iSPN extrasynaptic NMDARs increased at corticostriatal axospinous synapses following 
loss of dopaminergic innervation and then returned to normal as corticostriatal synaptic 
density rose with LID.
To determine whether these changes were common to SPNs, dSPNs were patch-clamped 
and the ratio between NMDAR and AMPAR currents measured. 2PLUG on spine heads 
revealed that the NMDAR to AMPAR current ratio at dSPN spines was unchanged 
following 6-OHDA lesioning and then increased after L-DOPA administration (Fig. 10c) 
including low dose L-DOPA (median: 1.4, lower quartile: 1.0, upper quartile: 2.1; n=60). To 
link these observations to synaptic transmission, corticostriatal axons were optically 
stimulated and the NMDAR to AMPAR current ratio measured. In normal recording 
conditions, this ratio did not change as a function of treatment condition (Fig. 10e). 
However, when glutamate uptake was blocked using TBOA, the NMDAR to AMPAR 
current ratio was significantly elevated in tissue from LID mice (Fig. 10f). These data are 
consistent with the proposition that the abundance of dSPN extrasynaptic NMDARs was 
unchanged at corticostriatal axospinous synapses following loss of dopaminergic innervation 
and then rose as corticostriatal synaptic density fell with high-dose L-DOPA treatment.
A summary of the collective findings are provided in Supplementary Table 3.
Discussion
There are four general conclusions that can be drawn from our studies. First, the loss of 
dopaminergic neurons innervating the striatum induces dendritic atrophy in both dSPNs and 
iSPNs through a mechanism that appears to be independent of dopamine. Second, both 
iSPNs and dSPNs manifest intrinsic and synaptic forms of homeostatic plasticity that should 
mitigate perturbations in average spiking rate accompanying PD and LID states. Third, 
global synaptic scaling was not a feature of the SPN adaptations in either PD or LID models. 
Fourth, the only adaptation found to be exclusively associated with LID was the restoration 
of iSPN axospinous synapses.
Near complete loss of SNc dopaminergic neurons was accompanied by a significant 
reduction in dendritic branching and total dendritic arbor length in both dSPNs and iSPNs. 
The reduction in dendritic length was approximately 25% in dSPNs and 20% in iSPNs. A 
similar dendritic atrophy is a common feature of SPNs in Parkinson's disease patients39, 40. 
Dendritic atrophy was not reversed by L-DOPA administration, suggesting it was not caused 
by deficits in striatal dopamine release. One factor released by SNc dopaminergic neurons 
that would be expected to have common effects on dSPNs and iSPNs is brain-derived 
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neurotrophic factor (BDNF)41, 42. In a number of neurons, BDNF signaling through TrkB 
receptors increases dendritic branching and complexity43. Given that previous studies with 
partial lesions did not find dendritic atrophy21, it is possible that there is a threshold of 
dopamine denervation for this phenomenon to occur.
Previous work has shown that profound dopamine depletion, mimicking advanced PD, 
induces a rapid loss of spines and glutamatergic axospinous synapses in iSPNs, but not 
neighboring dSPNs16. This observation gave a structural foundation for earlier biochemical 
studies showing that ionotropic glutamate receptors found at these synapses (GluA1, GluN1, 
GluN2B) are down-regulated by6-OHDA lesions44, 45, 46. What was left unresolved by these 
studies was the origin of the presynaptic terminal pruned. Our work demonstrated that much 
of this pruning was of corticostriatalaxospinous synapses, as their density was reduced by 
approximately 40% in iSPNs from parkinsonian mice. This conclusion is consistent with the 
recent observation that striatal immunoreactivity for cortically expressed vesicular glutamate 
transporter 1 (vGlut1)is down-regulated in parkinsonian rats, while the expression of vGlut2 
is unaltered20. It remains to be determined whether there is concomitant pruning of 
thalamostriatal axospinous synapses in this rodent model of PD, as seen in other PD 
models47, 48.
In addition to pruning excitatory corticostriatal synapses, iSPNs down-regulated their 
intrinsic excitability in response to 6-OHDA lesions. Both somatic excitabilityand dendritic 
excitability fell in iSPNs. The ionic mechanisms underlying this change remain to be 
determined, but it is clear that they complement the pruning of excitatory synapses to 
decrease iSPN spiking following dopamine depletion.
In contrast to iSPNs, dSPNs did not exhibit any obvious change in axospinous synapse 
density following induction of the parkinsonian state and the loss of excitatory D1R 
signaling. This finding contrasts with that of Suarez et al.,21 who reported a reduction in 
dSPN spine density following 6-OHDA lesioning. One potential explanation for the 
difference is that Suarez et al. used intrastriatal 6-OHDA injections to lesion dopaminergic 
fibers. Although this approach has several features of relevance to PD, intrastriatal 6-OHDA 
injections trigger a neuroinflammatory response which might induce non-specific spine 
loss49, 50. Why in our modeldSPNs exhibited intrinsic but not synaptic homeostatic 
plasticity is not clear. It is possible that D1R signaling, which is lost in the parkinsonian 
state, is necessary in dSPNs for de novo spine generation51.
Thus, iSPNs and dSPNs manifested compensatory, cell-specific homeostatic plasticity in the 
parkinsonian state. These adaptations should diminish the imbalance in the activity of direct 
and indirect pathway triggered by the loss of dopaminergic signaling. Work in profoundly 
parkinsonian rats suggests that these homeostatic adaptations are not successful in restoring 
the balanced excitability seen in the healthy striatum52, 53. However, in early stages of PD, 
where there still is a substantial dopaminergic innervation of the striatum, the homeostatic 
mechanisms described here, working in concert with biochemical adaptations described 
previously,54, 55could help maintain a balance in the average activity of dSPNs and iSPNs.
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However, not all the changes in SPNs were homeostatic. In addition to changes in intrinsic 
excitability and synapse number, sustained perturbations in neuronal activity often result in 
the global up- or down-regulation of synaptic strength, a phenomenon referred to as synaptic 
scaling56. Scaling preserves information stored in the relative weights of synaptic 
connections. Scaling did not occur in the PD models. In iSPNs, where spines were 
prunedfollowing dopamine depletion, residual synaptic strength was increased– not 
decreased as expected of a scaling mechanism. In dSPNs, where there was no change in 
axospinous synapse number, synaptic strength was decreased following dopamine 
depletion– not increased as expected of a scaling mechanism. These anti-homeostatic 
adaptations likely reflect the fact that dopamine not only controls intrinsic excitability but 
also synaptic plasticity2.
In principle, homeostatic adaptations in SPNs driven by dopamine depletion should be 
reversed by L-DOPA treatment. This was true in iSPNs. Consistent with recent anatomical 
work20, 21, 22, high dose L-DOPA treatment restored the density of functional axospinous, 
corticostriatal glutamatergic synapses. Importantly, treatment with a low-dose of L-DOPA 
did not restore iSPN spine deficits. In addition, somatodendritic excitability rose to levels 
indistinguishable from those of iSPNs in control mice. At face value, these observations 
suggest that iSPNs were restored to their normal, pre-parkinsonian state. However, there are 
reasons to doubt this conclusion. First, although our optogenetic experiments demonstrate 
that high dose L-DOPA treatment re-established functional corticostriatal connectivity, they 
do not show whether connectivity with the appropriate cortical regions were re-established. 
This question is now being pursued using anatomical approaches. Lastly, the fact that only 
highdoses of L-DOPA increased the density of corticostriatal synapses in iSPNs suggests 
that this adaptation could be linked to the network pathophysiology underlying LID.
In dSPNs, L-DOPA treatment partially reversed the changes in intrinsic excitability induced 
by the parkinsonian state. However, L-DOPA treatment did more than simply reverse 
depletion induced adaptations. Most notably, L-DOPA triggered the pruning of 
corticostriatal axospinous synapses. This adaptation was seen at both low and high doses of 
L-DOPA, dissociating it from the induction of dyskinesia per se.
As mentioned above, in a number of other neurons, sustained perturbations in activity – like 
those created by dopamine depletion – result in global synaptic scaling to restore activity to 
a predetermined set-point56. With global scaling of synaptic strength, relative synaptic 
weights sculpted by learning are preserved. Thus, cellular memories stored in synaptic 
weight are not erased or distorted. However, SPNs did not exhibit this type of synaptic 
scaling. Instead of scaling synaptic strength, SPNs eliminated axospinous synapses to 
maintain a stable synaptic input. This could reflect a process similar to what has been 
described as ‘local’ synaptic homeostatic scaling57. Here, activity-dependent potentiation of 
synapses triggers depression of neighboring synapses to stabilize regional synaptic weight. 
This kind of regional homeostatic mechanism might explain the stability of cortical 
excitation of SPNs in the parkinsonian state seen in our experiments using optogenetic 
approaches, as well as that seen by other susing electrical stimulation in vivo53.
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The situation in dSPNs appears to be more complicated. In the LID model, aggregate 
cortical synaptic excitation of dSPNs fell, as did spine density and the relative number of 
strong corticostriatal synapses. Taken at face value, this is inconsistent with the homeostatic 
model. It also seems inconsistent with work suggesting that LID is dependent upon aberrant 
strengthening of corticostriatal synapses triggered by the loss of depotentiation in dSPNs58. 
However, there are most likely two phases in the dSPN response to L-DOPA. During the 
active treatment (‘on’ L-DOPA), D1R stimulation could induce synaptic potentiation and an 
elevation in intrinsic excitability; this could trigger synaptic pruning. After the last L-DOPA 
dose (when our measurements were taken), striatal dopamine levels fall, pushing down 
dSPN excitability and enabling depotentiation of strong synaptic connections, shifting the 
distribution of synaptic amplitudes. The time course of these changes remains to be 
precisely mapped, but it would appear that the subtraction or addition of spines takes more 
than the 48 hours between L-DOPA injections in our experiments.
Although the mechanisms governing the subtraction or addition of axospinous synapses in 
SPNs are poorly understood, local Ca2+ signaling could be important. One piece of evidence 
that is consistent with this conclusion is that the loss of iSPN synapses following dopamine 
depletion is regulated by Cav1.3 L-type Ca2+ channels that are positioned near glutamatergic 
synapses16, 59. Furthermore, in our studies, the abundance of Ca2+ permeable extrasynaptic 
NMDARs was strongly correlated with spine pruning whether in iSPNs or dSPNs. Although 
it remains to be determined whether they are causally linked to pruning, extrasynaptic 
NMDARs are coupled to signaling pathways that destabilize spines60. The fact that the 
elevation in extrasynaptic NMDARs was celltype- and state-specific adds an important 
dimension to previous work correlating their striatal appearance and the pathophysiology of 
PD37.
The rapid and bidirectional effects of dopamine on the excitability of iSPNs and dSPNs have 
dominated basal ganglia models of PD for decades. This spatially diffuse 
modulation61, 62, 63serves to globally bias action selection, but it cannot determine precisely 
what actions are endorsed or vetoed. This function must be determined by the strength and 
pattern of corticostriatal connections with SPNs. These connections are sculpted by 
outcome-dependent release of dopamine. This sculpting is presumably what underlies 
striatal learning. In the severely parkinsonian state, L-DOPA administration continues to 
shape synaptic strength, but it is shaped in a way that is divorced from the outcome of action 
selection because it is not arbitrated by dopaminergic neurons6, 58. Moreover, synaptic 
connectivity in this state is also being sculpted by cell autonomous homeostatic mechanisms 
that have nothing to do with action selection outcomes. Viewed from this perspective, LID 
(and the parkinsonian state) can be seen as a manifestation of aberrant striatal learning, not 
simply an imbalance in direct and indirect pathway activity.
Methods
Animals
Male C57Bl/6 and FVB mice expressing enhanced green fluorescent protein (eGFP) or 
tdTomato under control of either the Drd1a or Drd2 receptor regulatory elements were used. 
All the mice used for experimentation were hemizygous for these transgenes26. For some 
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experiments, BAC transgenic mice were crossed with a transgenic line expressing channel 
rhodopsin (ChR2) in the cortex (Thy1-ChR2). All mice were 6-10 weeks of age prior to 
stereotaxic surgery and housed under a 12-h light/dark cycle with food and water provided 
ad libitum throughout the study. Protocols were reviewed and approved by the Northwestern 
Institutional Animal Care and Use Committee and Malmo-Lund Ethical Committee on 
Animal Research.
Unilateral model of PD and LID
Mice were anesthetized with an isoflurane precision vaporizer (Smiths Medical PM, Inc., 
Norwell, MA), placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA) with a 
Cunningham adaptor (Harvard Apparatus, Holliston, MI) and a hole was drilled over the 
medial forebrain bundle. After exposing the skull, 3.5μg of 6-OHDA HCl in 1μl volume of 
sterile saline with 0.02% ascorbic was injected using a calibrated glass micropipette 
(Drummond Scientific Company, Broomall, PA) pulled on a P-97 Sutter Instruments 
(Novato, CA) at the following coordinates: AP: -0.7, ML: 1.2, DV: -4.75. Sham operated 
mice underwent identical surgical procedures and were administered 1μl of vehicle (saline 
with 0.02% ascorbic acid) into the medial forebrain bundle. Mice were monitored daily post-
op and supplemented with saline injections and high fat/high sucrose food as needed based 
on prior studies64. Two weeks post-op mice underwent a cylinder test (Supplementary Fig. 
1a) to measure asymmetrical forelimb use to verify the lesion as previously described64. In 
brief, mice were placed in a 600 mL glass beaker for 3 min (subjects were not acclimated to 
the testing room or beaker) and number of ipsilateral and contralateral (to lesioned 
hemisphere) forelimb weight bearing paw contacts were counted; data are expressed as % 
contralateral paw contacts. Within 1-7 days of the cylinder test, mice underwent behavioral 
testing for abnormal involuntary movements (AIMs; Supplementary Fig. 1b) as previously 
described65, 66. In brief, mice were transferred to a behavioral testing room, placed in 
standard housing cages without bedding, and administered ip injections. Behavioral testing 
occurred every other day for a total of five test sessions. Four groups were tested: sham, 6-
OHDA lesion, 6-OHDA lesion + low-dose L-DOPA, and 6-OHDA lesion + high-dose 
(dyskinesiogenic) L-DOPA. The low-dose L-DOPA group received 1.0 mgkg-1 L-DOPA 
(eliciting very mild or no AIMs) for all five test sessions and the high-dose group received 
6.0 mgkg-1 and 12.0 mgkg-1 L-DOPA for the first two and last three behavioral sessions, 
respectively. Benserazide was coadministered at 12.0 mgkg-1 with all L-DOPA treatments. 
AIMs (axial, limb, and orolingual movements) were scored as previously described65, 66. In 
brief, abnormal axial, limb, and orolingual behaviors were observed for one minute every 
20min for a total of 180min and rated on a scale from 0-4 for each parameter; scores of 0 
equates no abnormal behavior, 1 exhibiting abnormal behavior for less than half of the one 
minute observation period, 2 exhibiting abnormal behavior for more than half of the 
observation period, 3 abnormal behavior for the entire observation period but was able to be 
interrupted, and 4 abnormal behavior for the entire observation period and resistant to 
interruption. Physiological experiments were performed 1-4 days after the last L-DOPA/
saline administration. Striatal and nigral sections from a subset of mice were stained with 
tyrosine hydroxylase to verify successful lesion.
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Brain slice preparation
Mice were anesthetized with a mixture of ketamine (50.0 mgkg-1) and xylazine (4.5 mgkg-1) 
and transcardially perfused with modified artificial cerebrospinal fluid (aCSF) containing (in 
mM) 124.0 NaCl, 3.0 KCl, 1.0 CaCl2, 2.0 MgCl2, 26.0 NaHCO3, 1.0 NaH2PO4, and 16.66 
glucose, brain removed and 240-275μm parasagittal slices sectioned. Slices were transferred 
to a holding chamber and incubated in aCSF containing (in mM) 2.0 CaCl2 and 1.0 MgCl2 
at 34° C for at least 30 min, after which the holding chamber was moved to room 
temperature for electrophysiology experiments.
Two-photon laser scanning microscopy and anatomy
iSPNs and dSPNs in the dorsolateral striatum were identified by somatic enhanced green 
fluorescent protein (eGFP) and tdTomato, respectively, using two-photon laser scanning 
microscopy (2PLSM) with an Ultima Laser Scanning Microscope system (Prairie 
Technologies, Middleton, WI) or a Zeiss LSM710 NLO with MaiThai laser (Spectra 
Physics, Santa Clara, CA). A DODT contrast detector system was used to provide a bright-
field transmission image in registration with the fluorescent images. The red tdTomato 
(554-581nm) and green eGFP (490-560 nm) were acquired with 810 nm excitation using a 
two-photon laser (Verdi/Mira laser) or 543 nm with a single photon laser (HeNe). SPNs 
were patched with video microscopy using either a Hitachi CCD camera and an Olympus 
X60/0.9 NA lens or an Axiocam CCD camera (Zeiss) and a W Plan-Apochormat 63×/1.0 
NA objective (Zeiss). For anatomical assessments whole cell images were obtained with 
0.389μm2 pixels with 0.5μm z-steps and sholl's analysis performed on 3D reconstructions 
with NeuroLucida (Williston, VT) or Imaris (Bitplane, AG Zurich, Switzerland). High 
magnification images of dendritic segments (proximal: <80μm from soma; distal: >80μm 
from soma) were acquired with 0.15μm2 pixels with 0.3μm z-steps. High magnification 
images were deconvolved in AutoQant (MediaCybernetics, Rockville, MD) and semi-
automated spine counting performed using 3D reconstructions in NeuronStudio (CNIC, 
Mount Sinai School of Medicine, New York). Total spine estimates were calculated by 
averaging proximal and distal spine densities for each cell and multiplying by the following: 
median total dendritic length for treatment group – (30 * median number of primary 
dendrites for treatment group). Thirty multiplied by the number of primary dendrites was 
subtracted from the total dendritic length because the first 30μm of a primary dendrite are 
aspiny or have minimal spines.
Electrophysiology
Patch pipettes were pulled from thick-walled borosilicate glass on a Sutter P-1000 puller. 
Pipette resistance was typically 3-4.5 MΩ when filled with recording solution. The internal 
recording solutions contained (in mM) 135.0 KMeSO4, 5.0 KCL, 0.16 CaCl2, 10.0 HEPES, 
2.0 Mg-ATP, 0.5 Na-GTP, 5 phosphocreatine-Tris, 5.0 phospocreatine-NA, and 0.1 
spermine or 120.0 CsMeSO3, 5.0 NaCl, 0.16 CaCl2, 10.0 TEA-CL (tetraethylammonium-
Cl), 10.0 HEPES, 5.0 QX-314, 4.0 Mg-ATP, 0.3 Na-GTP, or 130.0 CsMeSO3, 5.0 HEPES, 
0.25 EGTA, 10.0 Phosphocreatine-di(Na), 2.0 ATP-Mg, 0.5 GTP-Na, 5.0 TEA-Cl, 1.0 
QX-314; pH was adjusted to 7.25-7.30 and osmolarity 270-280 mosM. In experiments 
involving two-photon microscopy the internal recording solution lacked CaCl2 and 50μM 
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Alexa 568 fluor hydrazide sodium salt was added for visualization of cells and 200μM 
Fluo-4 pentapotassium to detect calcium signals. Slices were continuously perfused with 
carbogen (95% O2; 5% CO2)-bubbled aCSF. For whole-cell recordings, slices were 
transferred to a submersion-style recording chamber mounted on an Olympus BX51 upright, 
fixed stage microscope or on a Zeiss LSM 710 NLO; once whole-cell configuration was 
achieved the internal solution was allowed to equilibrate for at least 15 min prior to 
beginning experiments. Electrophysiological recordings were obtained using a Multiclamp 
700A or 700B amplifier with stimulation and display obtained as previously described25 
with custom-written shareware package Winfluor (John Dempster, Strathclyde Universty, 
Glasgow, UK), which automates and synchronizes the two-photon imaging and 
electrophysiological protocols or pClamp (Molecular Devices, Sunnyvale, CA). The 
amplifier bridge circuit was adjusted to compensate for serial resistance and monitored 
throughout the experiment. Recordings were performed at room temperature and filtered at 
1-2kHz.
Intrinsic excitability was assessed in current-clamp with 500 msec somatic current injection. 
Synaptic NMDA/AMPA ratios were determined in voltage-clamp with a Cs+ based internal 
solution and aCSF supplemented with 10.0μM Glycine, 50.0μM picrotoxin and 1.0μM TTX. 
Spines were visualized and somatic responses to glutamate uncaging at spines was tested 
with cells held at −70mV (AMPA component) and at +40mV (NMDA component). 
Stimulation was performed on 4 -5 spines per dendritic segment, with 1.5 sec between each 
spine stimulation. Stimulation at each voltage level was repeated three times and responses 
were averaged. Uncaging was performed as previously described67; MNI-glutamate (5 mM; 
Tocris Cookson) was superfused at 0.4ml h-1and uncaged using 1ms pulses of 720 nm light, 
controlled by a third Pockels cell modulator (model 302, Con Optics) and typically about 15 
mW in strength. Photolysis was adjusted to closely mimic spontaneously occurring AMPA 
EPSCs. To complement and expand the findings using uncaging techniques, neurons from 
Thy1-ChR2-D2 eGFP and Thy1-ChR2-D1 tdTomato were patched with a Cs+ based internal 
solution and ChR2 was stimulated with 473nm light using a blue LED (full-field 
stimulation) to excite all cortical afferents (CoolLED, Yorktown Heights, NY); light 
intensity was calibrated to ∼150pA response with cells held at -70mV. Similar to uncaging 
studies, the AMPA component and NMDA components were measured with cells held at 
-70mV and +40mV, respectively, in optogenetic experiments. For all NMDA/AMPA 
assessments NMDA component was measured 50 msec after the peak to minimize potential 
contamination by AMPA currents. To further assess synaptic properties corticostriatal 
AMPA-mediated miniature excitatory post-synaptic currents (mEPSCs) were assessed by 
asynchronous release achieved by substituting Ca2+ with Sr2+ as previously described34 and 
electrically stimulating between layers V and VI in the motor cortex with a parallel bipolar 
electrode (Frederick Haer & Co, Bowdoin, ME). StrEPSCs were collected during a 300 ms 
period beginning 50ms after each electrical stimulation (delivered once every 15 sec) in the 
presence of 10.0μM SR 95531 (gabazine) and 10.0μM (R)-CPP. Miniature events were 
analyzed using Minianalysis software (Synaptosoft, Decatur, GA) with detection parameters 
set at >5pA amplitude and individually verified. Between 50-100 sweeps were used for each 
cell for analysis. Access resistance was continuously measured and experiments were 
rejected if it changed significantly.
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Channel rhodopsin assisted circuit mapping
Cells from Thy1-ChR2-D2 eGFP were patched with a Cs+ based internal solution with 
100.0μM 4.0AP, 1.0μM TTX, 10.0μM Gabazine and 1.0μM CGP 35348 added to aCSF. 
Input-output curves were generated using full-field illumination (473 nm light; CoolLED) 
from 10%-80% LED power at 10% steps in voltage-clamp; each LED intensity was repeated 
3 times at 10sec intervals and data presented as average EPSC amplitude. For corticostriatal 
axospinous circuit mapping proximal (<80μm from the soma) and distal (>80μm from the 
soma) were identified and a Prairie Instruments blue laser (473nm) was targeted adjacent to 
a spine in voltage-clamp with minimal fixed diameter (approximately 1μm); 6-10 spines 
were sampled per dendritic segment. Laser intensity was calibrated to the minimum laser 
power to elicit at least one synaptic response from the series of spines; this minimum 
threshold was then doubled for circuit mapping. Synaptic responses were recorded six times 
at 10sec intervals and data presented as the average response.
Statistics
Data analysis was performed with Clampfit 9.2 (Molecular Devices, Inc., Sunnyvale, CA), 
Igor Pro 5.0 (WaveMetrics, Lake Oswego, OR), Matlab R2009b (Mathworks, Natic, MA), 
and Minianalysis software (Synaptosoft, Decatur, GA). Statistical analyses were performed 
using Sigmastat 3.5 (Systat Software Inc., San Jose, CA) and Prism 5 (GraphPad, La Jolla, 
CA). Data are reported as average ± S.E.M. or box and whisker plots showing median, 
quartiles, and range. Statistical evaluations were performed using Mann-Whitney U non-
parametric test of significance, Kruskal-Wallis non-parametric test with Dunns post-hoc, 
and two-way ANOVAs with Newman-Keuls post-hoc where appropriate. Differences were 
considered significant if p<0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. iSPN intrinsic and dendritic excitability was reduced in iSPNs from parkinsonian mice 
and restored by high-dose L-DOPA
Intrinsic excitability was assessed by somatic current injection. (a) Sample traces are 
provided with vertical and horizontal scale bars denoting 25mV and 200msec and (b) 
current-response curves (shaded regions illustrate S.E.M.). Intrinsic excitability was 
decreased in iSPNs from parkinsonian mice and restored by high-dose L-DOPA (control 
n=13; parkinsonian n=13; dyskinetic n=12; two-way ANOVA). Dendritic excitability was 
assessed by somatically driven theta burst stimulation.(c) Cartoon (left) and iSPN 2PLSM 
image provided (top right) with a high magnification 2PLSM image depicting dendritic 
segment with a line representing the region assessed for Ca2+ fluorescence (bottom); scale 
bars denote 10μm with an eccentricity denoting 80μm from the soma in the low 
magnification image.(d) Sample fluorescent traces provided with vertical and horizontal 
scale bars denoting 0.5 ΔF/F0 and 200msec, respectively. (e) Dendritic excitability was 
decreased in shaft (top; control median: 1.54 n=17; parkinsonian median: 1.25 n=19; 
dsykinetic median: 1.28 n=24) and spine heads (bottom; control median: 1.27 n=14; 
parkinsonian median: 1.05 n=23;dyskinetic median: 1.04 n=26) of parkinsonian mice and 
restored by high-dose L-DOPA; Kruskal-Wallis. Sample traces provided below 2PLSM 
images; *p<0.05; response areas refer to (S*ΔF/F0).
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Figure 2. dSPN intrinsic excitability was increased in parkinsonian mice and partially restored 
by high-dose L-DOPA with a decrease in dendritic excitability
(a) Sample traces are provided with vertical and horizontal scale bars denoting 25 mV and 
200 msec and (b) current-response curves (shaded regions illustrate S.E.M.). Intrinsic 
excitability was increased in dSPNs from parkinsonian mice and partially restored by high-
dose L-DOPA (control n=24; parkinsonian n=20; dyskinetic n=21; two-way ANOVA). 
Dendritic excitability was assessed by somatically driven theta burst stimulation. (c) Cartoon 
(left) and iSPN 2PLSM image provided (top right) with a high magnification 2PLSM image 
depicting dendritic segment with a line representing the region assessed for Ca2+ 
fluorescence (bottom); scale bars denote 10μm with an eccentricity denoting 80μm from the 
soma in the low magnification image. (d) Sample fluorescent traces provided with vertical 
and horizontal scale bars denoting 0.5 ΔF/F0 and 200msec, respectively.(e) dSPN dendritic 
excitability was decreased in the dendritic shaft (top; control median: 1.52 n=26; 
parkinsonian median: 1.01 n=22; dsykinetic median: 0.94 n=16) and spine heads(bottom; 
control median: 1.06 n=21; parkinsonian median: 1.35 n=24; dyskinetic median: 0.98 n=17) 
of high dose L-DOPA treated mice; Kruskal-Wallis. Sample traces provided below 2PLSM 
images; *p<0.05; response areas refer to (S*ΔF/F0).
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Figure 3. iSPN dendritic arborization is reduced in parkinsonian mice and is not restored by 
high-dose L-DOPA
iSPN neurons were patched and filled with Alexa 568, 2PLSM images obtained, and 
reconstructed in 3D. (a) Representative reconstructions of iSPNs from control (black), 
parkinsonian (blue), and dyskinetic (red)mice with eccentricities every 10μm from the soma. 
(b) Sholl analysis of reconstructed iSPNs; solid lines represent the mean with shaded regions 
illustrating S.E.M. (c) Total dendritic length was reduced in both parkinsonian (median: 
1,627μm) and dyskinetic mice(median: 1,622μm) compared to control(median: 2,333μm). 
(d) Number of branch points was unchanged by treatment conditions (controlmedian: 12.5, 
parkinsonian median: 13.0, dyskineticmedian: 16.0). (e) Number of primary dendrites was 
reduced in both parkinsonian (median: 5.0) and dyskinetic (median: 4.0) 
mice(controlmedian: 6.0). Control n=14, parkinsonian n=11, and dyskineticn=12; *p<0.05; 
Kruskal-Wallis.
Fieblinger et al. Page 22
Nat Commun. Author manuscript; available in PMC 2015 May 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. dSPN dendritic arborization is reduced in parkinsonian mice and is not restored by 
high-dose L-DOPA
dSPN neurons were patched and filled with Alexa 568, 2PLSM images obtained, and 
reconstructed in 3D. (a) Representative reconstructions of iSPNs from control (black), 
parkinsonian (blue), and dyskinetic (red) mice with eccentricities every 10μm from the 
soma. (b) Sholl analysis of reconstructed dSPNs; solid lines represent the mean with shaded 
regions illustrating S.E.M. (c) Total dendritic length was reduced in parkinsonian (median: 
3,388μm) and dyskinetic mice(median: 2,774μm) compared to control(median: 4,464μm). 
(d) Number of branch points was decreased in both parkinsonian (median: 25) and 
dyskinetic (median: 22.5) mice compared to control (median: 36). (e) Number of primary 
dendrites was decreased in parkinsonian (median: 6) and dyskinetic mice (median: 6) 
compared to control (median: 8). Control n=13, parkinsonian n=13, and dyskinetic n=11; 
*p<0.05; Kruskal-Wallis.
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Figure 5. iSPN axospinous synapses were reduced in parkinsonian mice and restored by high-
dose L-DOPA
(a) 2PLSM image of an iSPN (left) from a control mouse with circles delineating minimal 
proximal (40μm) and distal (80μm) distances from the soma. (b) Representative 2PLSM 
images of proximal dendritic segments from control (black), parkinsonian (blue), and 
dyskinetic (red)mice. (c) iSPN proximal spine density was decreased in parkinsonian mice 
(median: 0.83 spines/μm) and restored in dyskinetic mice (median: 1.11 spines/μm; 
controlmedian: 1.30 spines/μm). (d) iSPN distal spine density was also decreased in 
parkinsonian mic e(median: 0.64 spines/μm) and restored in dyskinetic mice (median 1.07 
spines/μm; controlmedian: 1.22 spines/μm). (e) Total number of spines were estimated based 
on spine density and dendritic anatomy data (Fig. 3); despite a restoration in spine density 
with dyskinesia, total number of spines remain below controllevels due to reduced dendritic 
surface area. Total spine estimates for controlmedian: 2,701 spines, parkinsonian median: 
1,171 spines, and dyskineticmedian: 1,622 spines; control n=16, parkinsonian n=17, 
dyskineticn=15; *p<0.05; scale bar denotes 10μm; Kruskal-Wallis.
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Figure 6. dSPN axospinous synapses were reduced in L-DOPA treated mice
(a) 2PLSM image of a dSPN (left) from a control mouse with circles delineating minimal 
proximal (40μm) and distal (80μm) distances from the soma. (b) Representative 2PLSM 
images of proximal dendritic segments from control, parkinsonian, and dyskinetic mice. 
dSPN proximal (c) and distal (d) spine density was decreased in L-DOPA treated mice 
compared to controls. (e) Total number of spines were estimated based on spine density and 
dendritic anatomy data (Fig. 4); dyskinetic mice (median: 2,096) had fewer spines than 
control (median: 4,715) and parkinsonian mice (median: 3,426); control n=16, parkinsonian 
n=17, dyskinetic n=15; *p<0.05;scale bar denotes 10μm; Kruskal-Wallis.
Fieblinger et al. Page 25
Nat Commun. Author manuscript; available in PMC 2015 May 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 7. Cortical axospinous synapses in iSPNs were lost in parkinsonian mice and rewired with 
high-dose L-DOPA
sCRACm was used to assess corticostriatal circuit function in iSPNs from control (black), 
parkinsonian (blue), and dyskinetic (red)mice. (a) Sample 2PLSM image depicting a 
patched iSPN (left) and dendritic region (right) assessed for functional corticostriatal 
circuitry; scale bars denote 10μm. Blue circles depict region stimulated by focal blue laser 
excitation of ChR2. (b) The cartoon segment of dendrite shows both cortical and thalamic 
input onto spines and shaft. Only axospinous synapses were tested for cortical circuitry; to 
the right of the experimental depiction are sample traces showing responses from a 
corticostriatal synapse, a presumed thalamostriatal synapse, and a second corticostriatal 
synapse; vertical scale bar denotes 5pA and horizontal scale bar 50msec. Both proximal (c) 
and distal (d) corticostriatal axospinous synapses were lost in iSPNs from parkinsonian mice 
and restored by dykinesiogenic L-DOPA (Proximal medians: control 76.92% n=15, 
parkinsonian 50.00% n=15, dyskinetic73.33% n=15; distal medians: control 76.19% n=15, 
parkinsonian 47.37% n=13, dyskinetic 71.43% n=15). (e) Individual corticostriatal 
optogenetically evoked EPSCs (oEPSC) were measured, representative traces are shown to 
the right of experimental diagram; vertical scale bar denotes 5pA and horizontal scale bar 
50msec. oEPSC amplitude was increased in iSPNs from parkinsonian mice and restored in 
dyskinetic mice. Full-field stimulation using a blue LED was used to assess overall circuit 
Fieblinger et al. Page 26
Nat Commun. Author manuscript; available in PMC 2015 May 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
strength. (f) Overall circuit strength was unchanged despite losing axospinous synapses 
parkinsonian mice sample traces provided (g) with vertical scale and horizontal scale bars 
denoting 100pA and 100msec, respectively. (h) Input-output curve demonstrating 
sublinearity of recorded data (solid line) and estimated linear summation (dashed line) from 
control cells. Box and whisker plots of minimal LED stimulation (i) (control median: 
86.67pA n=15, parkinsonian median: 237.7pA n=15, dyskinetic median: 170.3pA n=15) and 
maximal stimulation (j) (control median: 508.0pA n=15, parkinsonian median: 660.6pA 
n=15, dyskinetic median: 508.4pA n=15) demonstrate the lack of change in overall 
corticostriatal circuit strength.*p<0.05; Kruskal-Wallis.
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Figure 8. Cortical axospinous synapses in dSPNs were lost in dyskinetic mice
sCRACm was used to assess corticostriatal circuit function in iSPNs from control (black), 
parkinsonian (blue), and dyskinetic (red) mice. (a) Sample 2PLSM image depicting a 
patched dSPN (left) and dendritic region (right) assessed for functional corticostriatal 
circuitry; scale bars denote 10μm. Blue circles depict region stimulated by focal blue laser 
excitation of ChR2. (b) The cartoon segment of dendrite shows both cortical and thalamic 
input onto spines and shaft. Only axospinous synapses were tested for cortical circuitry; to 
the right of the experimental depiction are sample traces showing responses from a 
corticostriatal synapse, a presumed thalamostriatal synapse, and a second corticostriatal 
synapse; vertical scale bar denotes 5pA and horizontal scale bar 50msec. Both proximal (c) 
and distal (d) corticostriatal axospinous synapses were lost in dSPNs from dyskinetic mice 
(Proximal medians: control 75.00% n=13, parkinsonian 71.82% n=14, and dyskinetic 
48.53% n=18; distal medians: control 76.47% n=13, parkinsonian 66.97% n=14, and 
dyskinetic 51.47% n=14). (e) Individual corticostriatal optogenetically evoked EPSCs 
(oEPSC) were measured, representative traces are shown to the right of experimental 
diagram; vertical scale bar denotes 5pA and horizontal scale bar 50msec. EPSC amplitude 
data was separated into low and high EPSC amplitude groups by the median; in 
parkinsonian and dyskinetic mice there were fewer high amplitude synapses than in controls. 
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Full-field stimulation using a blue LED was used to assess overall circuit strength. (f) 
Overall circuit strength was reduced in parkinsonian and dyskinetic mice; sample traces 
provided (g) with vertical scale and horizontal scale bars denoting 100pA and 100msec, 
respectively. (h) Input-output curve demonstrating sublinearity of recorded data (solid line) 
and estimated linear summation (dashed line) from control cells. Box and whisker plots of 
minimal LED stimulation (i) (control median: 885.4pA n=13, parkinsonian median: 
435.8pA n=15, and dyskinetic median: 505.6pA n=11) and maximal stimulation (j) (control 
median: 1198.0pA n=13, parkinsonian median: 857.8pA n=15, and dyskinetic median: 
817.5pA n=11) demonstrate the decreased corticostriatal circuit strength in parkinsonian and 
dyskinetic mice.*p<0.05; Kruskal-Wallis and Mann-Whitney tests.
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Figure 9. Extrasynaptic NMDA/AMPA ratios in iSPNs were increased in parkinsonian mice
(a) 2PLSM image depicting an iSPN (left) with circles delineating proximal (40μm from 
soma) and distal (80μm from soma) dendritic segments and a high magnification image of a 
dendritic segment (middle) with yellow asterisks indicating regions targeted with uncaging 
laser; scale bars denote 10μm. To the right is a cartoon depicting regions exposed to 
glutamate due to uncaging (yellow circles). (b) Sample traces depicting uncaged glutamate-
induced responses used to assess NMDA/AMPA ratios (middle) and data from control 
(black), parkinsonian (blue), and dyskinetic mice (red); vertical and horizontal scale bars 
denote 10pA and 100msec, respectively. (c) NMDA/AMPA ratios in iSPNs were increased 
in parkinsonian mice (control median: 0.96 n=58 spines; parkinsonian median: 1.67 n=44 
spines; dyskinetic median: 1.07 n=43 spines). (d) Cartoon depicting full-field stimulation of 
an iSPN exciting all cortical inputs. (e) Synaptic NMDA/AMPA ratios (determined using 
cortical optogenetic stimulation)with sample traces on the left and data showing no change 
on the right; vertical and horizontal scale bars denote 100pA and 100msec, respectively 
(control median: 0.37 n=16; parkinsonian median: 0.54 n=17; dyskinetic median: 0.54 
n=16). (f) To verify findings with uncaged glutamate, full-field optogenetic stimulation was 
again tested in the presence of TBOA to engage both synaptic and extrasynaptic receptors. 
Sample traces provided on the left; again, NMDA/AMPA ratio was increased in 
parkinsonian mice, verifying that changes were due to extrasynaptic receptors (control 
median: 0.35 n=13; parkinsonian median: 1.14 n=16). *p<0.05; Kruskal-Wallis and Mann-
Whitney tests.
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Figure 10. Extrasynaptic NMDA/AMPA ratios in dSPNs were increased in dyskinetic mice
(a) 2PLSM image depicting a dSPN (left) with circles delineating proximal (40μm from 
soma) and distal (80μm from soma) dendritic segments and a high magnification image of a 
dendritic segment (middle) with yellow asterisks indicating regions targeted with uncaging 
laser; scale bars denote 10μm. To the right is a cartoon depicting regions exposed to 
glutamate due to uncaging (yellow circles). (b) Sample traces depicting uncaged glutamate-
induced responses used to assess NMDA/AMPA ratios (middle) and data from control 
(black), parkinsonian (blue), and dyskinetic mice (red); vertical and horizontal scale bars 
denote 10pA and 100msec. (c) NMDA/AMPA ratios in dSPNs were increased in dyskinetic 
mice (control median: 0.81 n=61 spines; parkinsonian median: 0.58 n=46 spines; dyskinetic 
median: 1.04 n=55 spines). (d) Cartoon depicting full-field stimulation with a dSPN exciting 
all cortical inputs. (e) Synaptic NMDA/AMPA ratios (determined using cortical optogenetic 
stimulation) with sample traces on the left and data showing no change on the right; vertical 
and horizontal scale bars denote 100pA and 100msec, respectively (control median: 0.43 
n=13; parkinsonian median: 0.61 n=13; dyskinetic median: 0.52 n=14). (f) To verify 
findings with uncaged glutamate, full-field optogenetic stimulation was again tested in the 
presence of TBOA to engage both synaptic and extrasynaptic receptors. Sample traces 
provided on the left; again, NMDA/AMPA ratio was increased in parkinsonian mice, 
verifying that changes were due to extra synaptic receptors (control median: 0.37 n=17; 
parkinsonian median: 1.16 n=15). *p<0.05; Kruskal-Wallis and Mann-Whitney tests.
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